photo

Mission:Guiding Principles

Mission:Guiding Principles

FOCUSED ON ADVANCING GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC RARE DISEASES

Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates and neuromuscular and cardiac programs, including SGT-003, for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, AVB-202-TT for the treatment of Friedreich’s ataxia, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases.

Guiding Principles

Solid is purpose-built to identify and develop the most promising approaches to address these diseases at all stages.

Singular Focus

Focused

We are focused on developing transformative treatments to improve the lives of patients with neuromuscular and cardiac diseases

Patient Centric

Patient Centric

We start with patients and their unmet needs.

Collaboration 2

Collaborative

We are working collectively with all stakeholders — industry, academia, government, and community — to advance our gene therapy candidates to better understand their potential to benefit patients.

Center Of Excellence

Center of Excellence

We are a catalyst bringing together the best knowledge to address all aspects of these diseases.